Hereditary Angioedema Therapeutics Global Market Report 2024

The hereditary angioedema therapeutics market has grown rapidly in recent years. It will grow from $5.74 billion in 2023 to $6.76 billion in 2024 at a compound annual growth rate (CAGR) of 17.6%. The expansion observed in the historical period can be attributed to factors such as improved diagnosis and awareness, the expansion of treatment access, research and development initiatives, patient advocacy and education efforts, and regulatory approvals in the field of hereditary angioedema therapeutics.

The hereditary angioedema therapeutics market is expected to see rapid growth in the next few years. It will grow to $13.47 billion in 2028 at a compound annual growth rate (CAGR) of 18.8%. The anticipated growth in the forecast period can be attributed to advancements in targeted therapies, global market expansion, developments in gene therapy, trends in personalized medicine, and collaborative efforts in research and treatment for hereditary angioedema. Key trends expected in the forecast period encompass global access initiatives, health economic outcomes research, strategies for early intervention, and the development of therapeutics specifically designed for pediatric hereditary angioedema.

The anticipated rise in the prevalence of hereditary angioedema is expected to drive the growth of the hereditary angioedema market in the future. Hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent severe swelling of the skin and mucous membranes, affects approximately 1 in every 50,000 individuals globally, with prevalence estimates ranging from 1,10,000 to 1,150,000. These episodes result in 15,000 to 30,000 emergency room visits annually in the US alone. The increasing incidence of hereditary angioedema is a significant factor propelling the growth of the hereditary angioedema market.

The growth of the hereditary angioedema therapeutics market is expected to receive a boost from increasing healthcare expenditure. The total amount of resources, including financial resources, allocated to healthcare goods and services within a specific period in a given geographical area is referred to as healthcare expenditure. With a projected annual growth of 5.1% between 2021 and 2030, reaching nearly $6.8 trillion, increased healthcare expenditure enables greater investment in research and development activities. This, in turn, supports the understanding of the underlying causes of hereditary angioedema and the development of innovative therapeutic solutions.

A notable trend gaining traction in the hereditary angioedema therapeutics market is the emphasis on product innovation. Leading companies in this market are actively involved in the development of groundbreaking products, including ligand-conjugated (LICA) investigational antisense medicine and gene therapy, to reinforce their market position. In a significant development, Intellia Therapeutics, a clinical-stage biotechnology company based in the US, introduced an Investigational New Drug (IND) named NTLA-2002 in March 2023. This innovative therapy, approved by the United States Food and Drug Administration for hereditary angioedema treatment, allows the company's ongoing Phase 1/2 trial to incorporate the US into the global Phase 2 segment. NTLA-2002, a candidate for in vivo genome editing, aims to permanently lower plasma kallikrein protein activity and prevent hereditary angioedema attacks after a single dose of therapy through the inactivation of the target gene, kallikrein B1 (KLKB1).

Major players in the hereditary angioedema therapeutics market are also investing in the development of bradykinin B2 receptor antagonists as part of their strategy to reach broader customer bases, drive increased sales, and enhance revenue. An example of this approach is evident in the activities of Cycle Pharmaceuticals, a UK-based biotechnology company. In September 2021, Cycle Pharmaceuticals launched SAJAZIR (icatibant) Injection, an approved treatment by the United States Food and Drug Administration for individuals dealing with Hereditary Angioedema (HAE). Positioned as a bradykinin B2 receptor antagonist, SAJAZIR (icatibant) Injection is specifically designed for the treatment of acute hereditary angioedema attacks in adults aged 18 and above. Its distinctive feature lies in the convenience of a prefilled syringe delivering a 30 mg dose of icatibant. Notably, patients have the capability to self-administer SAJAZIR subcutaneously, following appropriate training provided by healthcare professionals or registered nurses from Cycle Vita, upon recognizing symptoms of an HAE attack.

In February 2023, Takeda Pharmaceutical Company acquired Nimbus Lakshmi, Inc. from Nimbus Therapeutics, LLC. The acquisition, involving an undisclosed amount, enhances Takeda's late-stage pipeline, contributing to portfolio expansion and broadening its impact across multiple indications. Nimbus Lakshmi is a US-based company specializing in Tyrosine kinase 2 (TYK2) inhibitor NDI-034858.

Major companies operating in the hereditary angioedema therapeutics market report are Shire plc, Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., Adverum Biotechnologies Inc., Arrowhead Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., CENTOGENE N.V., GlaxoSmithKline plc., Eli Lilly and Company, Amgen Inc., AbbVie Inc., Incyte Corporation, BioMarin Pharmaceutical Inc., Dyax Corp., Salix Pharmaceuticals Inc., Pharvaris N.V., Innovent Biologics Inc., AstraZeneca plc, BeiGene Ltd., Jiangsu HenGrui Medicine Co. Ltd., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG ., Exelixis Inc., Lev Pharmaceuticals Inc., Kedrion Biopharma Inc., Pharos Pharmaceuticals Inc.

North America was the largest region in the global hereditary angioedema therapeutics market in 2023. Asia-pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hereditary angioedema therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main drug classes of hereditary angioedema therapeutics include C1 esterase inhibitor, selective bradykinin B2 receptor antagonist, kallikrein inhibitor, and others. C1 Esterase Inhibitor is a protein present in the fluid portion of blood that regulates the complement system's protein C1. These therapeutics are administered through intravenous, subcutaneous, and oral routes and are distributed via hospital pharmacies, retail pharmacies, and others. The application of hereditary angioedema therapeutics includes prophylaxis and on-demand treatment.

The hereditary angioedema therapeutics market research report provides hereditary angioedema therapeutics market statistics, including hereditary angioedema therapeutics industry global market size, regional shares, competitors with a hereditary angioedema therapeutics market share, detailed hereditary angioedema therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the hereditary angioedema therapeutics industry. This hereditary angioedema therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hereditary angioedema therapeutics market includes revenues earned by entities by diagnosis and evaluation, treatment, management of hereditary angioedema. The market value includes the value of related goods sold by the service provider or included within the service offering. he hereditary angioedema therapeutics market also includes of sales of tranexamic acid, danazol, intravenous and subcutaneous nano filtered purified plasma-derived human C1 esterase inhibitor concentrate, and lanadelumab. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.